Free public seminar: improving treatment of prostate cancer

Wednesday, 12 February 2014

Two experts will speak about diagnosis and treatment of prostate cancer in a free public seminar being held by the Freemason's Foundation Centre for Men's Health at the University of Adelaide on Monday 17 February.

Prostate cancer is the second most commonly diagnosed cancer in Australia and a common cause of cancer-related death in males. This free public seminar is an opportunity for members of the community to find out the latest information about the often controversial use of PSA (prostate-specific antigen) tests for diagnosis, and new drugs in development which offer some hope for men with aggressive forms of the disease.

The speakers at the public event are:

Associate Professor Anthony Lowe (CEO, Prostate Cancer Foundation of Australia): The Great PSA Testing Controversy: Does PSA Testing Do More Harm Than Good?

Associate Professor Ganesh Raj (2014 Freemasons Foundation Centre for Men's Health Visiting Lecturer; Urology Surgeon and Researcher, University of Texas Southwestern Medical Center): Drug development - Targeting the critical driver of prostate cancer.

This drug development program is part of a global research collaboration, of which the Adelaide Prostate Cancer Research Centre at the University of Adelaide is a member. Their work has been awarded funding from the United States Department of Defense.

WHAT: Free Public Seminar: Prostate Cancer Improvements in detection and treatment of prostate cancer
WHERE: Great Hall, Freemasons Building, 254 North Terrace, Adelaide
WHEN: 6.00-7.30pm, Monday 17 February 2014
COST: Free - but registration is essential. Call 8313 0514 or email: menshealth@adelaide.edu.au

For more information about the event, visit the website: www.adelaide.edu.au/menshealth

 

Contact Details

Mr David Ellis
Email: david.ellis@adelaide.edu.au
Website: https://www.adelaide.edu.au/newsroom/
Deputy Director, Media and Corporate Relations
External Relations
The University of Adelaide
Business: +61 8 8313 5414
Mobile: +61 (0)421 612 762